Raymond Lifestyle Q1 Results FY27: Net Loss of Rs 22 Cr for June 2026 Quarter

The Raymond Lifestyle Q1 results FY27 show consolidated revenue of Rs 1,515 Cr for the quarter ended 30 June 2026, +5.95% from Rs 1,430 Cr in Q1 FY26, as Raymond Lifestyle reported its numbers on 31 July 2026.

Raymond Lifestyle posted a net loss of Rs 22 Cr for the quarter, against a net loss of Rs 19 Cr a year earlier. Shares traded around Rs 699.6 on the NSE, down 1.53% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.

Click Here – Get Free Investment Predictions

Raymond Lifestyle Q1 Results FY27 Financial Highlights

The table below summarises Raymond Lifestyle's consolidated numbers for the quarter against the year ago period.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue	Rs 1,515 Cr	Rs 1,430 Cr	+5.95%
Gross Profit	(Rs 19 Cr)	(Rs 11 Cr)	-65.63%
Gross Profit Margin	-1.3%	-0.8%	-0.5 pts
Net Profit (PAT)	(Rs 22 Cr)	(Rs 19 Cr)	-13.98%
Net Profit Margin	-1.5%	-1.3%	-0.1 pts

Raymond Lifestyle Q1 FY27 Performance Analysis

Revenue growth was the standout number for the quarter. Sales rose +5.95% year on year to Rs 1,515 Cr, up from Rs 1,430 Cr in the year ago period, as demand held firm through the June quarter.

Margins came under pressure this quarter. Gross profit moved -65.63% year on year to a gross loss of Rs 19 Cr (-1.3% margin), growing slower than revenue or contracting outright, which suggests higher input costs or pricing pressure.

The release shows the net loss widening. Raymond Lifestyle reported a net loss of Rs 22 Cr for the quarter, larger than a net loss of Rs 19 Cr in Q1 FY26, a change of -13.98% that will concern investors.

Check the Univest Screener for Live Data

Raymond Lifestyle Q1 FY27: Key Business Factors

1. Revenue Growth Trajectory

Raymond Lifestyle reported revenue of Rs 1,515 Cr for the June 2026 quarter against Rs 1,430 Cr in the year ago period, a change of +5.95%. This pace of change is a primary swing factor behind the quarter's numbers, and investors typically track whether it holds up in the following quarters.

2. Gross Margin and Cost Trends

Gross profit moved from a gross loss of Rs 11 Cr in Q1 FY26 to a gross loss of Rs 19 Cr in Q1 FY27, a change of -65.63%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter's numbers reflect how Raymond Lifestyle managed that balance.

3. Bottom Line and Earnings Quality

The net loss widened from a net loss of Rs 19 Cr in Q1 FY26 to a net loss of Rs 22 Cr this quarter, a change of -13.98%. The widening loss is the key concern to watch going forward.

Dividend Details

Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Raymond Lifestyle.

Raymond Lifestyle Outlook for FY27

This quarter sets the tone for the rest of FY27. If the growth in revenue and widening loss in net profit persist, analysts are likely to revisit their FY27 estimates for Raymond Lifestyle. Investors should also watch input costs and demand trends in the pharmaceuticals sector through the year.

Raymond Lifestyle Stock Performance After the Results

Raymond Lifestyle shares traded around Rs 699.6 on the NSE, down 1.53% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.

Download the Univest iOS App or Univest Android App to track Raymond Lifestyle live share price and upcoming quarterly results.

Key Risks

Investors reading through Raymond Lifestyle's numbers should also weigh the following risks.

1. Margin and Input Cost Risk

Being in the pharmaceuticals sector, Raymond Lifestyle remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.

2. Execution and Working Capital Risk

Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter's trends should be read over a few quarters rather than in isolation.

3. Macro and Sector Risk

Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter's trends prove to be over FY27.

Conclusion

The Raymond Lifestyle Q1 results FY27 show revenue of Rs 1,515 Cr and a net loss of Rs 22 Cr for the quarter, against Rs 1,430 Cr and a net loss of Rs 19 Cr in Q1 FY26. Revenue growth and a wider net loss were the two moving parts this quarter. Investors tracking Raymond Lifestyle should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.

Frequently Asked Questions on Raymond Lifestyle Q1 Results FY27

When were the Raymond Lifestyle Q1 results FY27 announced?

Ans. They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.

What is the PAT in Raymond Lifestyle's Q1 FY27 results?

Ans. The net loss stood at Rs 22 Cr, compared with a net loss of Rs 19 Cr in Q1 FY26, a change of -13.98%.

What was the revenue in Raymond Lifestyle's Q1 FY27 results?

Ans. Revenue came in at Rs 1,515 Cr for the quarter, a change of +5.95%, compared with Rs 1,430 Cr in Q1 FY26.

Did Raymond Lifestyle declare a dividend with the Q1 FY27 results?

Ans. Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.

What is the outlook for Raymond Lifestyle after Q1 FY27?

Ans. Analysts will track whether the growth in revenue and widening loss in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.

How did the stock react to Raymond Lifestyle's Q1 FY27 results?

Ans. Shares traded around Rs 699.6 on the NSE, down 1.53% as the numbers came into focus.

Is Raymond Lifestyle a good buy after the Q1 FY27 results?

Ans. The quarter shows a net loss of Rs 22 Cr on revenue of Rs 1,515 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.